info@strategicmarketresearch.com
92, An Guha Lane, Arya Samaj Gali, Sambalpur, Odisha -768001
Indian Flag  IN: +91-826-083-6500
Home » Healthcare

Healthcare

Retinol-Binding Protein 4 Antagonist Market By Product (Tinlarebant (LBS-008), STG-001, Other Preclinical RBP4 Antagonists); By Application (Stargardt Disease Type 1, Geographic Atrophy, Metabolic Disorders); By End User (Specialty Ophthalmology Clinics, Hospitals, Inherited Retinal Disease Centers, Academic and Research Institutes); By Development Stage (Regulatory-Stage Candidates, Late-Stage Clinical Candidates, Early-Stage Clinical Candidates, Preclinical Candidates); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Retinol-Binding Protein 4 Antagonist Market: From Clinical Validation to Commercial Scale

The Global Retinol-Binding Protein 4 Antagonist Market was valued at USD 40 million in 2025 and is projected to reach <... Read More

Published Date: JUL- 2026 | No Of Pages:171 | $ 4485

Antibody Purification Services Market By Service Type (Protein A/G/L Affinity Purification, Antigen-Affinity Purification, Ion Exchange Chromatography, Hydrophobic Interaction Chromatography, Size Exclusion Chromatography, Low-Endotoxin Processing and Analytical Testing); By Application (Therapeutic Antibody Development, Diagnostics, Research, Biosimilar Development, Preclinical Studies); By End User (Pharmaceutical and Biotechnology Companies, CROs and CDMOs, Academic and Research Institutes, Diagnostic Laboratories); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Antibody Purification Services Market: Complex Modalities, GMP Outsourcing, and Analytical Testing Expand Contract Revenue

The Global Antibody Purification Services Market was valued at USD 1.25 billion in 2025 and is projected to reach USD 2.31 billion by 2032, expan... Read More

Published Date: JUL-2026 | No Of Pages:162 | $ 4485

Molluscum Contagiosum Treatment Market By Treatment Type (FDA-Approved Prescription Therapies, Physical Removal Procedures, Off-Label Topical Therapies, Supportive and Immune-Directed Treatments), By Administration Setting (Healthcare Provider-Administered Treatment, Home-Based Treatment), By Patient Group (Pediatric Patients, Adults, Immunocompromised Patients), By Distribution Channel (Dermatology and Pediatric Clinics, Hospital Outpatient Departments, Retail Pharmacies, Mail-Order Pharmacies, Patient-Support Services), By Geography, Segment Revenue Estimation, Forecast: 2026–2032

Molluscum Contagiosum Treatment Market: Prescription Approvals Create a Defined Dermatology Market

The Global Molluscum Contagiosum Treatment Market was valued at approximately USD 0.72 million in 2025 and is projected to reach approximately USD 1.32 million by 2032, ... Read More

Published Date: JUL-2026 | No Of Pages:190 | $ 4485

Uveal Melanoma Treatment Market By Treatment Type (Radiation Therapy, Surgical Treatment, Systemic Drug Therapy, Liver-Directed Therapy); By Application (Localized Uveal Melanoma, Unresectable or Metastatic Uveal Melanoma); By End User (Hospitals and Cancer Centers, Ocular Oncology Centers, Radiation Oncology Centers, Specialty Clinics and Infusion Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Uveal Melanoma Treatment Market — Specialized Local Care and Recurring Metastatic Therapy Reshape Commercial Value

The Global Uveal Melanoma Treatment Market was valued at USD 0.95 billion in 2025 and is project... Read More

Published Date: JUL-2026 | No Of Pages:157 | $ 4485

Prader-Willi Syndrome Treatment Market By Product (VYKAT XR (Diazoxide Choline Extended-Release), Recombinant Human Growth Hormone, Hormone Replacement Therapies, Metabolic and Symptom-Directed Medicines, Investigational Therapies, Supportive Care Services); By Application (Hyperphagia Management, Growth Failure and Body-Composition Management, Hormone Deficiency Management, Metabolic Complication Management, Sleep and Behavioral Symptom Management, Developmental and Nutritional Support); By End User (Hospitals, Specialty Endocrinology Clinics, Genetics and Rare-Disease Clinics, Multidisciplinary PWS Centers, Specialty Pharmacies, Homecare Settings); By Distribution Channel (Specialty Pharmacies, Hospital Pharmacies, Retail and Community Pharmacies, Public Growth Hormone Programs); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Prader-Willi Syndrome Treatment Market — Commercial Evolution, Access Dynamics, and Competitive Outlook

The Global Prader-Willi Syndrome Treatment Market was valued at USD 680 million in 2025 and is projected to... Read More

Published Date: JUL-2026 | No Of Pages:179 | $ 4485

Adrenoleukodystrophy Market By Disease Type (Childhood Cerebral Adrenoleukodystrophy, Adrenomyeloneuropathy, Adrenal Insufficiency, Adult Cerebral Adrenoleukodystrophy, Other Forms), By Treatment (Hematopoietic Stem Cell Transplantation, Gene Therapy, Adrenal Hormone Replacement, Symptomatic and Supportive Care, Emerging Oral Therapies), By Diagnostic Service (Newborn Screening, VLCFA Testing, ABCD1 Genetic Testing, Brain MRI, Adrenal Function Testing, HLA and Donor Matching), By End User (Hospitals and Transplant Centers, Leukodystrophy and Neurology Clinics, Genetic Testing Laboratories, Endocrinology Clinics, Academic and Clinical Research Institutions), By Geography, Segment Revenue Estimation, Forecast: 2026–2032

Adrenoleukodystrophy Market: Newborn Screening, Early Treatment, and the AMN Pipeline Reshape Rare-Disease Care

The Global Adrenoleukodystrophy Market was valued at USD 80 million in 2025 and is projected to reach USD 650 million by 2032, expanding at a CAGR of 34.9% ... Read More

Published Date: JUL-2026 | No Of Pages:170 | $ 4485

NLRP3 Inhibitor Market By Product (Dapansutrile, VTX3232, VTX2735, Ruvonoflast, BGE-102, ACI-19764, Usnoflast, Selnoflast, Other Investigational NLRP3 Inhibitors); By Application (Cardiometabolic Diseases, Parkinson’s Disease, Acute Gout, Recurrent Pericarditis, Cryopyrin-Associated Periodic Syndromes, Amyotrophic Lateral Sclerosis, Other Inflammatory and Neurodegenerative Disorders); By End User (Hospitals, Specialty Clinics, Academic and Clinical Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

NLRP3 Inhibitor Market: Clinical Assets Move Toward Commercial Validation

The Global NLRP3 Inhibitor Market was valued at USD 14.0 million in 2025 and is projected to reach U... Read More

Published Date: JUL-2026 | No Of Pages:182 | $ 4485

Drug-Coated Balloon Catheter Market By Product Type (Paclitaxel-Coated Balloon Catheters, Sirolimus-Coated Balloon Catheters); By Application (Peripheral Artery Disease, Coronary In-Stent Restenosis, Small-Vessel Coronary Disease, De Novo Coronary Lesions, Below-the-Knee Artery Disease, Arteriovenous Fistula Stenosis); By End User (Hospitals, Cardiac Catheterization Laboratories, Vascular Intervention Centres, Ambulatory Surgical Centres, Office-Based Laboratories); By Geography, Segment Revenue and Volume Estimation, Forecast, 2026–2032

Drug-Coated Balloon Catheter Market: Coronary Approval, Peripheral Durability and Sirolimus Competition Reshape Vascular Intervention

The Global Drug-Coated Balloon Catheter Market was valued at USD 1.30 billion in 2025 and is projected to reach USD 2.65 billion by 20... Read More

Published Date: JUL-2026 | No Of Pages:183 | $ 4485

NaV1.8 Inhibitors Market By Product (Suzetrigine/Journavx, LTG-001, LTG-305, STC-004, VX-993, Grünenthal NaV1.8 Inhibitor, Other Investigational NaV1.8 Inhibitors), By Application (Moderate-to-Severe Acute Pain, Postoperative Pain, Painful Diabetic Peripheral Neuropathy, Other Chronic Peripheral Neuropathic Pain), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Pain Clinics, Academic and Clinical Research Institutions), By Geography, Segment Revenue Estimation, Forecast: 2026–2032

NaV1.8 Inhibitors Market: A New Non-Opioid Pain Treatment Class Enters Commercial Healthcare

The Global NaV1.8 Inhibitors Market was valued at USD 0.06 billion in 2025 and is projected to reach USD 2.35 billion by 2032, expanding at a CAGR of  68.4% during 2026&n... Read More

Published Date: JUL-2026 | No Of Pages:170 | $ 4485

Postmenopausal Vaginal Atrophy Market By Treatment (Vaginal Estrogen, Vaginal Moisturizers and Lubricants, Prasterone, Ospemifene, Systemic Hormone Therapy, Regenerative and Energy-Based Treatments), By Product Form (Creams, Tablets and Inserts, Vaginal Rings, Oral Tablets, Gels and Moisturizers), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics), By Geography, Segment Revenue Estimation, Forecast: 2026–2032

Postmenopausal Vaginal Atrophy Market: Untreated GSM Population Supports Long-Term Therapy Demand

The Global Postmenopausal Vaginal Atrophy Market was valued at USD 3.10 billion in 2025 and is projected to reach USD 5.35 billion by 2032, expanding at a CAGR of 8.3% du... Read More

Published Date: JUL-2026 | No Of Pages:180 | $ 4485